Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)
Funding available for research on alcohol treatment, pharmacotherapy, and recovery, including medications, behavioral therapies, and translational research.
Funder: National Institutes of Health
Due Dates: June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision) | February 5, 2026 (New) | March 5, 2026 (Renewal/Resubmission/Revision) | June 5, 2026 (New) | July 5, 2026 (Renewal/Resubmission/Revision)
Funding Amounts: Up to $500,000 direct costs per year (prior approval required for requests at this level); project period up to 5 years.
Summary: Supports clinical trials on treatment and recovery for alcohol use disorder, including medications, behavioral therapies, and innovative technologies.
Key Information: Clinical trial is required; only human studies are eligible; applications requesting ≥$500,000 direct costs/year must contact NIH at least 6 weeks before submission.
Description
This opportunity, issued by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) at NIH, solicits R01 applications for clinical trials focused on treatment and recovery from alcohol use disorder (AUD). The scope includes, but is not limited to, research on:
- Medications development (including new compounds, repurposed drugs, and treatments for comorbid AUD and psychiatric disorders)
- Precision medicine approaches
- Behavioral therapies and mechanisms of behavioral change (MOBC)
- Recovery processes, including risk/resilience factors, trajectories, and interventions to sustain recovery
- Translational research bridging basic science and clinical application
- Innovative methods and technologies (e.g., digital health, telemedicine, real-time data capture, new analytics)
Special emphasis is placed on research addressing health disparities, underserved populations, sex/gender differences, and comorbidities. Only human studies are eligible; preclinical animal studies are not permitted.
Applications that focus on prevention, community-based interventions, poly-substance use, or organ-specific diseases are not responsive.
